Stimulation of the left ventricular endocardium to deliver cardiac resynchronization therapy is an option for patients in whom conventional epicardial pacing is not possible. One potential limitation of pacing the endocardium via the trans-atrial septal approach is that the pacing lead may disrupt the integrity of the mitral valve.
| CASE
Stimulation of the left ventricular endocardium to deliver cardiac resynchronization therapy is an option for patients in whom conventional epicardial pacing is not possible. One potential limitation of pacing the endocardium via the trans-atrial septal approach is that the pacing lead may disrupt the integrity of the mitral valve.
A 65-year-old man with a history of myocardial infarction, pulmonary embolism and Factor V Leiden mutation underwent a dual-chamber pacemaker insertion for sick sinus syndrome. He had ongoing, symptomatic atrial tachyarrhythmias despite six ablation procedures, with evidence of significantly impaired left ventricular (LV) systolic function. Medications included warfarin, bisoprolol 10 mg od and ramipril 10 mg od. He was also prescribed mexiletine 200 mg bd for a high burden of frequent ventricular ectopics.
He underwent upgrade to a biventricular defibrillator (CRTD) (ongoing breathlessness, poor LV systolic function and 80% right ventricular, RV pacing) and subsequent catheter ablation of the atrioventricular node. At the time of implant, echocardiography demonstrated mild mitral regurgitation. A LV lead (Attain Performa, Medtronic, Minneapolis, USA) was implanted via the coronary sinus into a posterolateral vein, where it gave acceptable pacing parameters (thresholds of <2.5 V without phrenic nerve stimulation in LV2-LV3, LV2-LV4, LV3-RV coil). However, the lead required deactivation within a month due to insurmountable phrenic nerve stimulation (despite testing in all available vectors with higher pulse widths and lower outputs). In addition, the atrial lead had displaced. Other than the large posterolateral vein, there were no other viable venous epicardial tributaries for LV lead placement.
Given the lack of alternative favorable, epicardial venous options for LV stimulation, he was referred for a trans-septal LV endocardial lead to deliver cardiac resynchronization therapy (CRT), in addition to a right atrial (RA) lead revision. An LV endocardial lead (Medtronic 6254, 85 cm) was successfully implanted via a trans-atrial septal approach (Figure 1 ), using a previously described technique 1 and the epicardial LV lead was removed. Despite excellent pacing parameters during follow-up and an initial clinical improvement, his breathlessness was worse by 6 months. Transthoracic echocardiography demonstrated severe mitral regurgitation; transesophageal echocardiography (TEE) confirmed that this was likely to be due to a combination of splinting of the mitral valve apparatus (posterior leaflet, P2 scallop) by the LV lead, in addition to ischemic tethering ( Figure 2 , Video S1). The case was discussed at a multidisciplinary cardiac devices meeting in the presence of electrophysiologists, cardiac surgeons, general cardiologists and cardiac imaging specialists. The LV endocardial lead was considered to be contributing significantly to the severe mitral regurgitation. The options of a surgical lead removal with or without mitral valve repair/replacement or percutaneous lead extraction were considered. At that stage, the LV lead had been implanted for 10 months and it was concluded that a percutaneous approach would be less invasive and carry less procedural risk than cardiothoracic surgery. The patient was in full agreement with this decision and consented to percutaneous removal. The procedure was performed under general anesthesia, with intraprocedural TEE. The generator and leads were mobilized. A firm standard stylet was advanced to the tip of the LV endocardial lead and the active fixation helix retracted. With gentle traction alone, the lead detached from the LV endocardium and was pulled through the interatrial septum (Video S2), leaving a residual atrial septal defect (Figure 3 ). There was an improvement of mitral leaflet apposition but persistence of mitral regurgitation due to ischemic tethering of P2/3 ( Figure 3) . The body of a 7F femoral sheath was passed over the LV lead in order to maintain venous access without additional venepuncture. A Boston Scientific CS Hook and 130-degree subselector facilitated coronary venography. The main (and only) posterolateral vein had several subbranches. A quadripolar LV lead (Attain Performa, Medtronic, Minneapolis, USA) was placed in the same posterolateral cardiac vein; however, the final lead position was different here to that of the original CRT implant (Figure 4 ). On this occasion, the capture threshold in this position was 1.8 V at 1 ms without evidence of phrenic nerve stimulation at high output. These parameters were accepted and the lead attached to the existing generator and placed in a prepectoral pocket. The wound was closed in routine fashion. The patient made a good recovery from the general anesthetic, was without any neurological insult upon discharge, and reported an improved exercise tolerance and less breathlessness at 6 months postprocedure.
| DISCUSSION
Left ventricular endocardial leads are an alternative way of providing LV stimulation and thus delivering biventricular pacing in those in whom the epicardial venous route has failed. There is evidence from both animal and clinical endocardial pacing for CRT, 5 patients had a system infection requiring extraction; all cases were reported to be successful without complication but further detail was not given. 6 In this patient, the LV lead had been in situ for 10 months prior to extraction. Given it was splinting the mitral valve apparatus, there was concern about potential damage to the valve upon removal in addition to arterial embolization. The risk of embolic stroke during interventions within the arterial system is well described within the transcatheter aortic valve implantation (TAVI) cohort of patients; there is a high prevalence of subclinical infarcts on neurological imaging and clinical cerebrovascular accidents. 8 There are, however, no published reports of transcutaneous extraction of endocardial LV leads, and therefore, the prevalence of such complications is unknown. Importantly, stimulation of the LV endocardium is also possible without interference with the mitral valve apparatus. Betts et al have described delivering energy via a radiofrequency needle from within a steerable sheath placed against the mid-septum of the right ventricle, creating a transventricular passage to the LV endocardium. As there is no lead in the left atrium (LA), it may be that the risk of embolic stroke is lower; no strokes were reported in 10 patients over an 8-month follow-up period, but the longer term outcomes are needed. 9 In addition, the LV lead in this technique does not traverse the mitral valve apparatus, and therefore, mechanical disruption and splinting of the valve leaflets as occurred in this case may be avoided using this approach. Finally, the clinical feasibility of wireless intracardiac LV endocardial stimulation for the delivery of biventricular pacing has been described among patients who have failed to improve with a conventional CRT approach. Unlike the single cardiac pacing units currently used for RV pacing, 10 the WiSE-CRT pacing system (EBR Systems, Inc., Sunnyvale, California, USA) comprises a subcutaneous ultrasound pulse generator and battery in addition to a separate transcatheterdelivered 9-mm electrode. This can deliver LV endocardial stimulation within 3 ms of sensing a RV pacing spike from a preexisting pacemaker, enabling LV endocardial stimulation but without the presence of a pacing lead in the arterial system of the left heart. Among the 54 patients implanted across two small studies, the mean clinical response to CRT was 74% (which is notable given this group are self selected non responders to conventional CRT). 11, 12 Longer term efficacy and safety data are awaited, but results are certainly promising and this too may represent a tangible approach for delivering CRT via LV endocardial stimulation, without the risk of disruption to the mitral valve.
| CONCLUSION
Splinting and mechanical disruption of the mitral valve apparatus is an important longer-term consideration in patients receiving an endocardial LV lead. Percutaneous removal of an endocardial LV lead is feasible and safe. A multidisciplinary team approach is important to appreciate and plan for the risks specific to the case. Finally, TEE guidance is invaluable to provide real-time visualization of the mitral valve apparatus before, during, and after instrumentation.
